

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/606,763		06/29/2000	Hui Chen	1440.1043-001 7609		
21005	7590	06/10/2003	•			
		OĶ, SMITH & RI	EXAMINER			
530 VIRGII P.O. BOX 9	133			KAM, CHIH MIN  ART UNIT PAPER NUMBER		
CONCORD	, MA 01	742-9133				
				1653 DATE MAILED: 06/10/2003	17	

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No		Applicant(s)	
		09/606,763	09/606,763 CHEN ET AL.		
	Office Action Summary	Examiner		Art Unit	
		Chih-Min Kam		1653	
Period fo	The MAILING DATE of this c mmunication apport	pears on the cove	r sheet with the co	orrespondence address	
THE I - Exter after - If the - If NC - Failu - Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period or re to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, how y within the statutory mi will apply and will expire t, cause the application	ever, may a reply be time nimum of thirty (30) days SIX (6) MONTHS from to to become ABANDONED	oly filed will be considered timely. the mailing date of this communication. (35 U.S.C. § 133).	
1)🖂	Responsive to communication(s) filed on 14 A	<u> April 2003</u> .			
2a)⊠	This action is <b>FINAL</b> . 2b) ☐ Th	is action is non-f	inal.		
3)⊡ Dispositi	Since this application is in condition for allowations of claims				
4)🖂	Claim(s) <u>12,13,17,19,37-42,90 and 91</u> is/are p	ending in the ap	plication.		
1	4a) Of the above claim(s) is/are withdraw	wn from consider	ation.		
5)🖂	Claim(s) 12,13,17,19,38-42 and 91 is/are allow	ved.			
6)⊠	Claim(s) 37 and 90 is/are rejected.				
7)	Claim(s) is/are objected to.				
8)	Claim(s) are subject to restriction and/or	r election require	ment.		
Applicati	on Papers				
9) 🗆 -	The specification is objected to by the Examine	r.			
10) 🔲 🖯	Γhe drawing(s) filed on is/are: a)□ accep	oted or b)⊡ objec	ed to by the Exam	niner.	
	Applicant may not request that any objection to the	e drawing(s) be he	ld in abeyance. Se	e 37 CFR 1.85(a).	
11) 🗌 🗆	The proposed drawing correction filed on	_ is: a)∏ approv	ed b)∐ disapprov	red by the Examiner.	
_	If approved, corrected drawings are required in rep	•	tion.		
i	The oath or declaration is objected to by the Ex	aminer.			
Priority u	nder 35 U.S.C. §§ 119 and 120				
13)	Acknowledgment is made of a claim for foreign	priority under 3	5 U.S.C. § 119(a)	-(d) or (f).	
a)[	☐ All b)☐ Some * c)☐ None of:				
	1. Certified copies of the priority documents	s have been rece	eived.		
	2. Certified copies of the priority documents	s have been rece	ived in Applicatio	n No	
	3. Copies of the certified copies of the prior application from the International Bur ee the attached detailed Office action for a list of the control of the certified copies of the prior applications.	reau (PCT Rule	17.2(a)).	· ·	
1 _	cknowledgment is made of a claim for domestic		•		n).
a)	☐ The translation of the foreign language procedures to the compact of the compact is made of a claim for domestic the compact is made of a claim for domestic the compact in the compact	visional applicati	on has been rece	ived.	,
Attachment		. •			
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	4) 5) 6)		PTO-413) Paper No(s) stent Application (PTO-152)	
U.S. Patent and Tra PTO-326 (Rev	• • • • •	tion Summary		Part of Paper No. 17	



Application/Control Number: 09/606,763

Art Unit: 1653

#### **DETAILED ACTION**

#### Status of the Claims

1. Claims 12, 13, 17, 19, 37-42, 90 and 91 are pending.

Applicants' amendment filed on April 14, 2003 (Paper No. 16) is acknowledged, and applicants' response has been fully considered. Claims 17, 19 and 37-42 have been amended, and new claims 90 and 91 have been added. Claims 12, 13, 17, 19, 37-42, 90 and 91 are examined.

# **Objection Withdrawn**

2. The previous objection of claim 19 and 38-42 is withdrawn in view of applicants' amendment to the claims, and applicants' response at page 4 in Paper No. 16.

# Rejection Withdrawn

#### Claim Rejections - 35 USC § 112

3. The previous rejection of claim 17 under 35 U.S.C. 112 second paragraph, is withdrawn in view of applicants' amendment to the claims, and applicants' response at page 4 in Paper No. 16.

# Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- 4. Claims 37 and 90 are rejected under 35 U.S.C. 102(a) as being anticipated by Heinegard et al. (WO 98/46253).



Application/Control Number: 09/606,763

Art Unit: 1653

Heinegard *et al.* teach a pharmaceutical composition comprising COMP, fragments or analogs for prevention or treatment of arthritic conditions. The pharmaceutical composition comprises a purified bovine, rat or human COMP (page 6, lines 3-20; page 9, lines 14-27; page 15, lines 7-14, 23-28) and one or more arthritogenic substances such as collagen II, IX or XI, or aggrecan (page 15, lines 1-6; claims 37 and 90).

In response, applicants indicate the amended claim 37 is directed to a composition comprising purified COMP in a calcium-replete conformation, while the composition of Heinegard *et al.* comprises COMP purified in the presence of EDTA rather than calcium, thus the composition of Heinegard *et al.* comprises COMP of a different conformation from the COMP in the presence of calcium (page 5 of the response). The argument is not found persuasive because Heinegard *et al.* not only teach the purification of rat COMP in the presence of EDTA, it also indicate COMP may be isolated from naturally isolated material as described in Hedbom *et al.*, J. Biol. Chem. 267, 6132-6136 (1992) (page 15, lines 7-14), which does not include EDTA in the buffer used for purification of bovine COMP (page 6132, right column, Fig. 1), thus COMP of Heinegard *et al.* may also be the COMP in a calcium-replete conformation, which meets the criteria of claim 37.


### Conclusion

5. Claims 37 and 90 are rejected. It appears claims 12, 13, 17, 19, 38-42 and 91 are free of prior art.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).







Art Unit: 1653

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (703) 308-9437. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, Ph. D. can be reached on (703) 308-2923. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-0294 for regular communications and (703) 308-4227 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Chih-Min Kam, Ph. D. CHK Patent Examiner

\*\*\*

June 7, 2003

CHRISTOPHER C. F. LOW SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1800